Joint research starting immediately on Alzheimer’s, Parkinson’s, schizophrenia, geriatric psychiatry, as well as neurological diseases that are unique to the Jewish population
KAHR's leading drug candidate, now in clinical trials, is based on a compound that targets cancer cells, weakens their defenses and activates a local immune response
Recent comments